EOFLOW

EOFlow Initiates Eco-Friendly Disposal Campaign for EOPatch in Korea Embracing and Integrating Environmental, Social, and Governance (ESG)

▶EOFlow will collect, process, and dispose of used EOPatch pumps in an environmentally safe manner ▶EOFlow will set up an Incentive Program for this Campaign EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that the Company is initiating an environmentally friendly disposal campaign to minimize the impact of used EOPatch pumps on the environment. As there are no environmental regulations or guidelines for proper disposal of used medical devices in Korea, used patc...

Nov. 09. 2021
EOFlow to Raise 100 Billion Korean Won and Offer Stock Split Capital Raised Will Be Used For Global Market Expansion

▶ 100 billion Won to be raised with new common stock offering, to be followed by a 2:1 stock split EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will raise some 100 billion Won with new common stock offering, after which it will do a 2:1 stock split. The Company will make a new public offering of its common stocks. The company will issue up to 3,000,000 shares of common stocks, representing 25.99% of the current total number of issued shares. The...

Oct. 28. 2021
EOFlow and Sinocare Establish a Joint Venture Company

▶ Sinocare is China’s Largest Diabetes Management Instrument Manufacturer ▶ Joint venture company to launch a full-scale effort for clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China ▶ High growth expected from EOPatch business in China where world’s largest diabetes population live EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will establish a joint venture company “SINOFLOW Co., Ltd...

Oct. 27. 2021
EOFlow Begins Clinical Study of its Wearable Insulin Pump “EOPatch” on People With Type 2 diabetes in Korea

▶ This clinical study involves ten leading university hospitals and up to one hundred and thirty-six people with Type 2 diabetes. It is Korea’s largest ever clinical study employing insulin pumps. ▶ This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company completed enrollment of first patient in a clinical study on type 2 diabetes for its wearable in...

Oct. 14. 2021
EOFlow Completes its First Shipment to Europe

▶ EOFlow’s European exclusive distributing partner Menarini to showcase the EOPatch at EASD 2021 EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has made its first shipment to Europe today. After launching the wearable insulin pump in Korea this March and obtaining the CE certification in May, EOFlow is now expanding its reach to Europe, starting with the first shipment completed on September 30. EOFlow officially launched its EOPatch, Korea’s first (and the w...

Sep. 30. 2021
EOFLOW and K-Bio Health sign an MOU

K-Bio Health and EOFLOW sign an MOU to cooperate in developing and commercializing wearable automated insulin delivery solutions. K-Bio Health is one of the largest healthcare-focused development & testing labs supported by the Korean Ministry of Health. You can read more about the news at one of the links below, all of which are in Korean only: http://www.biospectator.com/view/news_view.php?varAtcId=6281 http://www.mdtoday.co.kr/mdtoday/index.html?no=333586 http://www.yakup.com/news/index.html?mode=view&nid=222513 http://www.dailymedi....

Oct. 01. 2018
EOFLOW's product chosen as a 'Top 100 Science Spinoffs'

EOFLOW was recently informed that SPINOFF.COM had chosen EOFLOW's 'tiny wearable artificial pancreas' as one of 'the Top 100 Science Spinoffs.' The product has 'entered 2 % out of 5,000 global science spinoffs according to the following criteria: uniqueness of the technology/product, high commercial potential and positive impact to the humanity’s well-being,' according to SPINOFF.COM. You can find out more about SPINOFF.COM here: http://www.spinoff.com You can read about us on SPINOFF.COM here: http://w...

Aug. 16. 2018
EOFLOW mentioned as a major new medical device company in an article

EOFLOW was mentioned as one of four medical device companies in Korea developing world-class product by Hankyung, a major economic newspaper in Korea. Read the article with this link (in Korean only): http://news.hankyung.com/health/article?aid=2018080661121

Aug. 09. 2018
EOFLOW will be at the 2018 EASD, Berlin, Germany (10/2 - 10/4)

EOFLOW will exhibit at the 2018 54th EASD (European Association for the Study of Diabetes) held in Berlin, Germany, 10/02 - 10/04/2018. EOFLOW's booth is 3.Q02. Please contact us in advance if you'd like to arrange a meeting with our marketing team: info@eoflow.com

Aug. 06. 2018
EOFLOW presents to President Moon

EOFLOW presented its company and product to President Moon of Korea who visited our campus today. Pres. Moon announced a major overhaul program on the medical device regulations at the campus. EOFLOW was given the opportunity to present itself to Pres. Moon and a group of high-level government officials including the Minister of Health and Welfare and Minister of Small and Medium Enterprises afterward. The news is covered by almost all major news outlets, and here are a few of those links: Yonhap News Agency: http://www.yonha...

Jul. 19. 2018
EOFLOW's JDRF partnership chosen as a top-10 event

The recent announcement of partnership between JDRF and EOFLOW in developing an integrated wearable automated insulin delivery system makes news again. This time, the JDRF support was chosen as one of the '10 Events that Rattled Medtech in 1Q18' by MD+DI (Medical Device + Diagnostic Industry) newsletter. You can read about us and 9 other significant events here: https://www.mddionline.com/top-10-medtech-stories-1q18

Jul. 04. 2018
EOFLOW will be at the 2018 ADA, Orlando (6/23-25)

EOFLOW will exhibit its EOPatch wearable disposable insulin delivery product (and more) at the 2018 American Diabetic Association's 78th Scientific Session held in Orlando, Florida, 6/23 - 6/25/2018. EOFLOW's booth is 423. Please contact us in advance if you'd like to arrange a meeting with our marketing team: info@eoflow.com

Jun. 20. 2018
EOFLOW covered in a major newspaper article

Maeil Business News Korea (www.mk.co.kr), one of the most widely read economics newspapers in Korea, discusses EOFLOW's wearable insulin pump in its article covering the new medical trend of focusing on improved user experience. To read the Korean article, click the link below: http://news.mk.co.kr/newsRead.php?year=2018&no=343754

May. 31. 2018
EOFLOW investment story on TV

MTN (Money Today Network), one of the most popular financial TV networks in Korea, runs a story on how Huons Global, EOFLOW's exclusive distribution partner in Korea, invests in EOFLOW in its in-depth story that covers the recent trend of established Korean bio and pharma companies identifying and investing in promising startup biotech companies. The video clip and text of the clip can be found in the link here, in Korean only: http://news.mtn.co.kr/newscenter/news_viewer.mtn?gidx=2018052111062224948 &n...

May. 28. 2018
EOFLOW closes two back-to-back rounds of funding

EOFLOW announces the closing of its Series-C and C+ rounds of funding. Through this unusual back-to-back funding rounds with two different valuations (with the C+ being higher than the C-round that closed unannounced a month earlier), the company has raised a total of 14Billion KRW (about $14M) from four investors, of which two are existing shareholders of EOFLOW. With the latest rounds of funding, combined with the recent award from JDRF (Juvenile Diabetes Research Foundation) and some fresh gove...

May. 04. 2018

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here